

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99

- 30

11. A hybridoma cell that produces a monoclonal antibody that binds immunologically to a DFF40 DNA fragmentation factor.
12. The hybridoma cell of claim 11, wherein the antibody does not bind immunologically to other human polypeptides.
13. A polyclonal antisera, antibodies of which bind immunologically to a DFF40 DNA fragmentation factor.
14. The antisera of claim 13, wherein said antisera is derived from an animal other than a human.
15. An isolated nucleic acid comprising a region, or the complement thereof, encoding a DFF40 DNA fragmentation factor or an allelic variant thereof.
16. The nucleic acid of claim 15, wherein the DFF40 DNA fragmentation factor is human.
17. The nucleic acid of claim 16, wherein said DNA fragmentation factor has the amino acid sequence of SEQ ID NO:2.
18. The nucleic acid of claim 17, wherein said nucleic acid sequence comprises the coding region having the sequence of SEQ ID NO:1 or the complement thereof.
19. The nucleic acid of claim 15, wherein said nucleic acid is selected from the group consisting of genomic DNA, complementary DNA and RNA.

002231-15484250

20. The nucleic acid of claim 19, wherein said nucleic acid is a complementary DNA and further comprises a promoter operably linked to said region, or the complement thereof, encoding said DNA fragmentation factor.
- 5 21. The nucleic acid of claim 20, further comprising a polyadenylation signal operably linked to said region encoding said DNA fragmentation factor.
22. The nucleic acid of claim 21, further comprising an origin of replication.
- 10 23. The nucleic acid of claim 22, wherein said nucleic acid is a viral vector selected from the group consisting of retrovirus, adenovirus, herpesvirus, vaccinia virus and adeno-associated virus.
- 15 24. The nucleic acid of claim 23, wherein said nucleic acid is packaged in a virus particle.
25. The nucleic acid of claim 22, wherein said nucleic acid is packaged in a liposome.
- 20 26. An isolated oligonucleotide of between about 15 and about 50 consecutive bases of a nucleic acid, or complement thereof, encoding a DFF40 DNA fragmentation factor.
27. The oligonucleotide of claim 26, wherein the DNA fragmentation factor is human.
- 25 28. The oligonucleotide of claim 26, wherein the nucleic acid is the coding region of SEQ ID NO:1.
29. The oligonucleotide of claim 26, wherein the oligonucleotide is about 15 bases in length.
- 30

002227-158260

30. The oligonucleotide of claim 26, wherein the oligonucleotide is about 17 bases in length.
- 5 31. The oligonucleotide of claim 26, wherein the oligonucleotide is about 20 bases in length.
32. The oligonucleotide of claim 26, wherein the oligonucleotide is about 25 bases in length.
- 10 33. The oligonucleotide of claim 26, wherein the oligonucleotide is about 50 bases in length.
34. A plasmid construct comprising a first nucleic acid encoding a DFF40 DNA fragmentation factor.
- 15 35. The construct of claim 34, further comprising a first promoter active in eukaryotic cells positioned 5' to said first nucleic acid.
36. The construct of claim 35, further comprising a second nucleic acid encoding a DFF45 DNA fragmentation factor.
- 20 37. The construct of claim 36, wherein said construct further comprises an internal ribosome entry site (IRES), wherein said IRES is positioned 3' to the upstream nucleic acid and 5' to the downstream nucleic acid.
- 25 38. The construct of claim 36, wherein said construct further comprises a second promoter functional in eukaryotic cells, wherein said second promoter is positioned 5' to said second nucleic acid.

39. The construct of claim 35, wherein said first promoter is selected from the group consisting of CMV IE, SV40 IE, RSV,  $\beta$ -actin, tetracycline regulatable and ecdysone regulatable.
- 5 40. The construct of claim 38, wherein said second promoter is selected from the group consisting of CMV IE, SV40 IE, RSV,  $\beta$ -actin, tetracycline regulatable and ecdysone regulatable.
- 10 41. The construct of claim 35, further comprising a polyadenylation signal positioned 3' to said first nucleic acid.
- 15 42. The construct of claim 38, further comprising (i) a first polyadenylation signal positioned 3' to said first nucleic acid and (ii) a second polyadenylation signal positioned 3' to said second nucleic acid.
43. The construct of claim 41, wherein said polyadenylation signal is from BGH, thymidine kinase or SV40.
- 20 44. The construct of claim 42, wherein said polyadenylation signals are from BGH, thymidine kinase or SV40.
45. The construct of claim 34, wherein said expression construct is a viral vector.
- 25 46. The construct of claim 45, wherein said viral vector is selected from the group consisting of retrovirus, adenovirus, vaccinia virus, herpesvirus and adeno-associated virus.
- 30 47. A method of inducing apoptosis in a cell comprising the step of providing said cell with a DFF40 DNA fragmentation factor, wherein the provision of said DFF40 to said cell results in apoptosis.

48. The method of claim 47, wherein said DFF40 is provided as a protein complex comprising a DFF45 DNA fragmentation factor, and wherein said DFF45 is altered, with respect to wild-type DFF45, such that it lacks anti-apoptotic function but retains DFF40-chaperone function.
49. The method of claim 47, wherein said DFF40 is provided as a protein complex comprising a DFF45 DNA fragmentation factor, and further comprising causing said DFF45 to be cleaved.
50. The method of claim 49, wherein the cleavage is effected by increasing the activity of caspase 3.
51. The method of claim 47, wherein said providing comprises contacting said cell with a first expression construct comprising a first nucleic acid encoding a DFF40 polypeptide and a promoter functional in eukaryotic cells wherein said first nucleic acid is under the control of said promoter.
52. The method of claim 47, further comprises providing a factor selected from the group consisting of a histone, a high mobility group protein and a nuclear factor.
53. The method of claim 51, wherein said expression construct comprises a viral vector.
54. The method of claim 51, wherein said viral vector is selected from the group consisting of retrovirus, adenovirus, vaccinia virus, herpesvirus and adeno-associated virus.

55. The method of claim 51, wherein said promoter is selected from the group consisting of CMV IE, SV40 IE, RSV,  $\beta$ -actin, tetracycline regulatable promoter and ecdysone regulatable promoter.
- 5 56. The method of claim 51, further comprising a polyadenylation signal.
57. The method of claim 56, wherein said polyadenylation signal is from BGH, thymidine kinase or SV40.
- 10 58. The method of claim 51, wherein said expression construct further comprises a second nucleic acid encoding a DFF45 polypeptide, and wherein said DFF45 is altered, with respect to wild-type DFF45, such that it lacks anti-apoptotic function but retains DFF40-chaperone function.
- 15 59. The method of claim 58, wherein said expression construct further comprises an internal ribosome entry site (IRES), wherein said IRES is positioned 3' to the upstream nucleic acid and 5' to the downstream nucleic acid.
- 20 60. The method of claim 58, wherein said expression construct further comprises a second promoter functional in eukaryotic cells, wherein said second nucleic acid is under the control of said second promoter.
- 25 61. The method of claim 51, further comprising providing to said cells a second expression construct comprising a second nucleic acid encoding a DFF45 polypeptide and a second promoter functional in eukaryotic cells wherein said second nucleic acid is under the control of said second promoter.
62. The method of claim 47, wherein said cell is a tumor cell.

002221 "T 544260

5  
10  
15  
20  
25

- 63. The method of claim 62, wherein said tumor cell is derived from a tissue selected from the group consisting of brain, lung, liver, spleen, kidney, lymph node, small intestine, blood cells, pancreas, colon, stomach, breast, endometrium, prostate, testicle, ovary, skin, head and neck, esophagus, bone marrow and blood tissue.
- 64. The method of claim 48, wherein said complex is encapsulated in a liposome.
- 65. A method for inhibiting the growth of a cancer cell comprising the step of contacting a cancer cell with a DNA fragmentation factor designated DFF40 under conditions permitting the uptake of said DNA fragmentation factor by said cell, wherein the presence of said DFF40 in said cell induces apoptosis.
- 66. The method claim 65, wherein inhibition of growth may be measured by reduced proliferation, reduced cell migration, increase in contact inhibition, reduction in soft agar growth or restoration of cell cycling.
- 67. The method of claim 65, wherein said cancer cell is within a subject.
- 68. The method of claim 67, wherein the subject is a human.
- 69. The method of claim 65, wherein said DFF40 is provided as a protein complex comprising a DFF45 DNA fragmentation factor, and wherein said DFF45 is altered, with respect to wild-type DFF45, such that it lacks anti-apoptotic function but retains DFF40-chaperone function.
- 70. The method of claim 65, wherein said DFF40 is provided as a protein complex comprising a DFF45 DNA fragmentation factor, and further comprising causing said DFF45 to be cleaved.



5  
10  
15  
20  
25  
30

71. The method of claim 70, wherein the cleavage is effected by increasing the activity of caspase 3.
72. The method of claim 65, wherein said providing comprises contacting said cell with a first expression construct comprising a first nucleic acid encoding a DFF40 polypeptide and a promoter functional in eukaryotic cells wherein said first nucleic acid is under the control of said promoter.
73. The method of claim 72, wherein said expression construct further comprises a second nucleic acid encoding a DFF45 polypeptide, and wherein said DFF45 is altered, with respect to wild-type DFF45, such that it lacks anti-apoptotic function but retains DFF40-chaperone function.
74. The method of claim 73, wherein said expression construct further comprises an internal ribosome entry site (IRES), wherein said IRES is positioned 3' to the upstream nucleic acid and 5' to the downstream nucleic acid.
75. The method of claim 73, wherein said expression construct further comprises a second promoter functional in eukaryotic cells, wherein said second nucleic acid is under the control of said second promoter.
76. A method for treating cancer comprising the step of contacting a tumor cell within a subject with a nucleic acid (i) encoding a DFF40 DNA fragmentation factor and (ii) a promoter active in said tumor cell, wherein said promoter is operably linked to the region encoding said DNA fragmentation factor, under conditions permitting the uptake of said nucleic acid by said tumor cell.
77. A method of identifying a modulator of DFF40 activity comprising the steps of:
  - (i) providing a cell expressing a DFF40/DFF45 complex;

- (ii) contacting said cell with a candidate substance;
- (iii) activating DFF40; and
- (iv) comparing the apoptosis of the cell in step (iii) with the apoptosis observed when said candidate substance is not added,

5

wherein an alteration in apoptosis indicates that said candidate substance is a modulator said apoptotic activity.

10

78. The method of claim 77, wherein said cell is a tumor cell.

79. The method of claim 77, wherein said apoptosis is measured using a parameter selected from the group consisting of DNA fragmentation, DNA condensation, DFF40 expression, nuclease activation, caspase activation, and DFF cleavage.

15

80. The method of claim 77, wherein said candidate substance is a chemotherapeutic or radiotherapeutic agent.

20

81. The method of claim 77, wherein said candidate substance is selected from a small molecule library.

82. The method of claim 77, wherein said candidate substance is a protein.

83. The method of claim 77, wherein said candidate substance is a DFF45 analogue.

25

84. The method of claim 77, wherein said candidate substance is a high mobility group (HMG) protein analogue.

85. The method of claim 84, wherein said HMG protein is HMG-1.

30

86. The method of claim 84, wherein said HMG protein is HMG-2.

87. The method of claim 84, wherein said HMG protein is HMG-14.

88. The method of claim 77, wherein said candidate substance is a nuclear factor.

89. The method of claim 88, wherein said protein is an histone.

90. A modulator of apoptotic activity identified according to a method comprising the steps of:

- (i) providing a cell expressing a DFF40/DFF45 complex;
- (ii) contacting said cell with a candidate substance;
- (iii) activating DFF40; and
- (iv) comparing the apoptosis of the cell in step (iii) with the apoptosis observed when said candidate substance is not added,

wherein an alteration in apoptosis indicates that said candidate substance is a modulator said apoptotic activity.

91. An isolated DNA fragmentation factor complex for regulating chromatin stability, said complex comprising a DFF40 polypeptide and a DFF45 polypeptide.

92. The complex of claim 91, wherein said DFF40 subunit has the sequence of as set forth in SEQ ID NO:2.

93. The complex of claim 81, wherein said DFF45 subunit has the sequence of as set forth in SEQ ID NO:4.

94. A method of producing a functional DNA fragmentation factor comprising:

- (i) providing to a cell
  - (a) a first nucleic acid encoding a DFF40 polypeptide; and
  - (b) a second nucleic acid encoding a DFF45 polypeptide; and
- (ii) expressing said complex in a cell,

5

wherein the coexpression of said polypeptides allows for the formation of a functional DFF40 polypeptide.

95. The method of claim 94, further comprising the step of causing said DFF45  
10 polypeptide to be cleaved by caspase 3.

96. The method of claim 94, wherein said first and said second nucleic acids are  
contained in the same expression construct and both are under the control a first  
promoter.  
15

97. The method of claim 96, where said expression construct further comprises an  
internal ribosome entry site (IRES) positioned 3' to the upstream gene and 5' to the  
downstream gene.

20 98. The method of claim 94, wherein said first and said second nucleic acids are  
contained in the same expression construct and are under the control a first and a second  
promoter, respectively.

25 99. The method claim 94, wherein said first and said second nucleic acids are  
contained in different expression constructs and are under the control a first and a second  
promoter, respectively.

100. The method of claim 94, wherein said second nucleic acid encodes a DFF45  
polypeptide that is altered, with respect to wild-type DFF45, such that it lacks anti-  
30 apoptotic function but retains DFF40-chaperone function.